Atorvastatin causes regression of endometriotic implants in a rat model

Basit Öğe Kaydı
dc.authoridGungor, Tayfun/0000-0002-7869-9662
dc.authorwosidbayraktar, nilufer/Y-8758-2018
dc.authorwosidYilmaz, Bulent/HKE-5048-2023
dc.authorwosidYilmaz, Bulent/GPK-8613-2022
dc.contributor.authorYilmaz, Bulent
dc.contributor.authorOzat, Mustafa
dc.contributor.authorKilic, Sevtap
dc.contributor.authorGungor, Tayfun
dc.contributor.authorAksoy, Yasemin
dc.contributor.authorLordlar, Nese
dc.contributor.authorSut, Necdet
dc.date.accessioned2024-06-12T10:52:48Z
dc.date.available2024-06-12T10:52:48Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractEndometriotic implants were induced surgically in female Wistar albino rats, which were randomly divided into three groups. The rats in group I (n = 10) and group II (n = 9) were given 2.5 mg/kg/day intraperitoneal and oral atorvastatin, respectively, for 28 days. Group III (n = 9) was given no medication (control). The mean volume and weight of explants in group I were significantly lower (both P < 0.05) compared with group III. Histopathological score of the implants was significantly tower in groups I and II, when compared with group III (P < 0.01 and P < 0.05, respectively). There were significant reductions in explant concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 in group I (P < 0.01 and P < 0.001, respectively) and group II (both P < 0.01) compared with group III while staining due to tissue inhibitor of metalloproteinase 2 was significantly higher in group I (P < 0.01) and group II (P < 0.01) compared with group III. Moreover, explant concentration of superoxide dismutase was significantly increased in groups I and II compared with group III (both P < 0.05). In conclusion, atorvastatin causes significant regression of endometriotic implants in rats. Moreover, intraperitoneal atorvastatin seems to be more effective than oral atorvastatin. (C) 2009, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.rbmo.2009.11.004
dc.identifier.endpage299en_US
dc.identifier.issn1472-6483
dc.identifier.issn1472-6491
dc.identifier.issue2en_US
dc.identifier.pmid20113969en_US
dc.identifier.scopus2-s2.0-77649222612en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage291en_US
dc.identifier.urihttps://doi.org/10.1016/j.rbmo.2009.11.004
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18839
dc.identifier.volume20en_US
dc.identifier.wosWOS:000274958800018en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofReproductive Biomedicine Onlineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAtorvastatinen_US
dc.subjectRat Endometriosis Modelen_US
dc.subjectSuperoxide Dismutaseen_US
dc.subjectVEGFen_US
dc.subjectMMP-9en_US
dc.subjectTIMP-2en_US
dc.subjectEndothelial Growth-Factoren_US
dc.subjectMatrix Metalloproteinasesen_US
dc.subjectTissue Inhibitoren_US
dc.subjectEutopic Endometriumen_US
dc.subjectEstrogen-Receptoren_US
dc.subjectOxidative Stressen_US
dc.subjectIn-Vitroen_US
dc.subjectPeritonealen_US
dc.subjectExpressionen_US
dc.subjectExplantsen_US
dc.titleAtorvastatin causes regression of endometriotic implants in a rat modelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu